Inhibikase Therapeutics, Inc. Detailed Financials

Full historical quarterly statements

Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue00000000
Cost of Goods Sold000007K7K7K
Gross Profit00000-7K-7K-7K
R&D Expenses10.8M6.4M7.6M5.3M10.5M7.2M4.2M3.1M
Operating Expenses18.2M13.8M12.8M10.8M14.6M12.9M5.8M5.1M
Operating Income-18.2M-13.8M-12.8M-10.8M-14.6M-12.9M-5.8M-5.1M
Other Income / Gains1.8M1.0M838K917K919K796K49K91K
Net Income-16.4M-12.7M-11.9M-9.9M-13.7M-12.1M-5.8M-5.0M
EPS (Diluted)-0.17-0.13-0.13-0.11-0.15-0.17-0.65-0.66
Reported CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Gross Profit Ratio00000000
General And Administrative Expenses00000000
Selling And Marketing Expenses00000000
Selling General And Administrative Expenses7.4M6.8M5.6M5.9M5.2M5.7M1.6M2.0M
Other Expenses0642K-493K-358K-1.2M000
Cost And Expenses18.2M13.8M12.8M10.8M14.6M12.9M5.8M5.1M
Interest Income1.5M1.0M838K917K919K796K49K91K
Interest Expense00000000
Depreciation And Amortization0024K24K13K7K7K7K
Ebitda-16.4M-13.1M-13.2M-11.2M-15.8M-12.1M-5.8M-5.0M
Ebitdaratio00000000
Operating Income Ratio00000000
Income Before Tax-16.4M-12.7M-11.9M-9.9M-13.7M-12.1M-5.8M-5.0M
Income Before Tax Ratio00000000
Income Tax Expense00000000
Net Income Ratio00000000
Epsdiluted-0.17-0.13-0.13-0.11-0.15-0.17-0.65-0.66
Weighted Average Shs Out98.3M98.3M90.1M90.0M89.5M69.4M8.9M7.5M
Weighted Average Shs Out Dil98.3M98.3M90.1M90.0M89.5M69.4M8.9M7.5M